SMYD3 inhibitor / GSK, Stanford University - LARVOL DELTA

SMYD3: a new regulator of adipocyte precursor proliferation at the early steps of differentiation. (PubMed, Int J Obes (Lond)) - "Our study describes an important role of SMYD3 as a newly discovered regulator of adipocyte precursor proliferation during the early steps of adipogenesis."

Journal • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • SMYD3

SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. (PubMed, Cell Rep) - "SMYD3 overexpression is associated with decreased CD8 T cell infiltration and poor response to neoadjuvant pembrolizumab. These data support combining SMYD3 depletion strategies with checkpoint blockade to overcome anti-PD-1 resistance in HPV-negative HNSCC."

IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD8 • DNMT1 • SMYD3 • UHRF1

Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors. (PubMed, J Chem Inf Model) - "Although one unexplained outlier exists, we obtain excellent statistical ranking across the set of compounds from the ESMACS protocol and good agreement between calculations and experiments for the relative binding free energies from the TIES protocol. ESMACS and TIES are again found to be powerful protocols for the accurate comparison of the binding free energies."

Journal • Oncology • SMYD3